The PERL Study is a clinical trial that is designed to test whether the existing medication allopurinol can prevent or slow down kidney disease in people with type 1 diabetes. Allopurinol is a medicine that has been widely used for over 50 years to decrease high uric acid levels in the blood and prevent gout. If the PERL Study can show that allopurinol can also protect kidney function in people with type 1 diabetes, we will have a new, safe and inexpensive tool to prevent or delay kidney failure that can be used at the earliest stages of renal injury. This would be a major advance for the many people with diabetes who are at risk for kidney problems.About 480 people with type 1 diabetes will participate in PERL. The study will last 3 years, and kidney function will be measured periodically to see if this treatment is effective.
Contact us at 1-866-701-3636 for more information on this study.
What does this study involve?
- Study participants take the study medication (allopurinol or placebo) each day for 3 years.
- At the beginning, middle and end of the study (a total of 4 times), a special test of kidney function, lasting about 4 hours, is performed at LMC Research.
- Other study visits (12 over 3 years) take about 1 hour and can be done at an LMC Research center (if you live nearby) or at a clinic or office close to your home.
- All study-related procedures and tests are provided at no charge. Participants receive a small payment for their time. Parking and transportation costs may be reimbursed.
You may be eligible for this clinical trial if you:
- Are 18 years or older
- Have been diagnosed with Type 1 (insulin-treated) Diabetes for at least 8 years
- Have had early signs of decreased kidney function on blood and/or urine tests
Find out if you qualify to participate in this study.
Call us today at 1-866-701-3636 or fill out the contact form below.
No Fields Found.